Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 5/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 5/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.33 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.33 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16577239 | 0.81 | KCNH2 (0.36) | KCNH2KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL14745244 | 0.80 | KCNH2 (0.36) | KCNH2KDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL14745248 | 0.80 | KCNH2 (0.36) | PRKAG1PRKAA1PRKAB1KCNH2KDM4E | |
| SCHEMBL14741158 | 0.79 | KCNH2 (0.35) | KCNH2KDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL14745375 | 0.79 | PDE3B (0.37) | KCNH2KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL14740829 | 0.77 | SLC16A3 (0.45) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL14741099 | 0.77 | PARP1 (0.41) | PRKAG1PRKAA1PRKAB1KCNH2KDM4E | |
| SCHEMBL14745092 | 0.77 | PARP1 (0.43) | PRKAG1PRKAA1PRKAB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14745228 | 0.77 | GRM1 (0.38) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL14758821 | 0.77 | KCNH2 (0.38) | KCNH2KDM4EALDH1A1MAPTPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016039936-A2 | MONOCYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | claimed |
| EP-2750505-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | claimed |
| WO-2013033240-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| US-9650395-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650395-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650395-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| WO-2016039936-A2 | MONOCYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2750505-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033240-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033240-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | PRKAG1 3736/4885PRKAA1 2503/4885PRKAB1 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.